BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15355898)

  • 21. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment with eldecalcitol (1α, 25-dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3) suppresses bone turnover and leads to prevention of bone loss and bone fragility in ovariectomized rats.
    Takeda S; Smith SY; Tamura T; Saito H; Takahashi F; Samadfam R; Haile S; Doyle N; Endo K
    Calcif Tissue Int; 2015 Jan; 96(1):45-55. PubMed ID: 25467010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.
    Kumru S; Yildiz AA; Yilmaz B; Sandal S; Gurates B
    Gynecol Endocrinol; 2007 Oct; 23(10):556-61. PubMed ID: 17952760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
    Kangas L; Härkönen P; Väänänen K; Peng Z
    Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of letrozole on hippocampal and cortical catecholaminergic neurotransmitter levels, neural cell adhesion molecule expression and spatial learning and memory in female rats.
    Aydin M; Yilmaz B; Alcin E; Nedzvetsky VS; Sahin Z; Tuzcu M
    Neuroscience; 2008 Jan; 151(1):186-94. PubMed ID: 18061360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
    Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study.
    Chavassieux P; Garnero P; Duboeuf F; Vergnaud P; Brunner-Ferber F; Delmas PD; Meunier PJ
    J Bone Miner Res; 2001 Jan; 16(1):89-96. PubMed ID: 11149494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cumulative Effects of Strontium Ranelate and Impact Exercise on Bone Mass in Ovariectomized Rats.
    Aveline P; Cesaro A; Mazor M; M Best T; Lespessailles E; Toumi H
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
    Bauss F; Lalla S; Endele R; Hothorn LA
    J Rheumatol; 2002 Oct; 29(10):2200-8. PubMed ID: 12375334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
    Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats.
    Goss PE; Qi S; Hu H
    J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):233-40. PubMed ID: 19429427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoplastic effects of exemestane in premenopausal breast cancer model.
    Kubatka P; Sadlonova V; Kajo K; Machalekova K; Ostatnikova D; Nosalova G; Fetisovova Z
    Neoplasma; 2008; 55(6):538-43. PubMed ID: 18999884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressive effects of genistein dosage and resistance exercise on bone loss in ovariectomized rats.
    Nakajima D; Kim CS; Oh TW; Yang CY; Naka T; Igawa S; Ohta F
    J Physiol Anthropol Appl Human Sci; 2001 Sep; 20(5):285-91. PubMed ID: 11759267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats.
    Mohamed I; Yeh JK
    J Endocrinol; 2009 Aug; 202(2):317-25. PubMed ID: 19420010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
    Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
    Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats.
    Bonnet N; Laroche N; Beaupied H; Vico L; Dolleans E; Benhamou CL; Courteix D
    J Appl Physiol (1985); 2007 Aug; 103(2):524-33. PubMed ID: 17478603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
    Ominsky MS; Li X; Asuncion FJ; Barrero M; Warmington KS; Dwyer D; Stolina M; Geng Z; Grisanti M; Tan HL; Corbin T; McCabe J; Simonet WS; Ke HZ; Kostenuik PJ
    J Bone Miner Res; 2008 May; 23(5):672-82. PubMed ID: 18433301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.